Impact of pharmacists ACCESs to clinical information on the quality and the continuity of care in poly-medicamented community patients: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN74420611

Enrollment

170

Registered

2008-06-18

Start date

2007-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-related problems from multiple prescription drugs Signs and Symptoms Drug-related problems

Interventions

All pharmacists in the area of Laval were invited to a three-hour workshop on the interpretation of laboratory results. They also have access to a consultation service with pharmacists currently worki

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Family doctors or residents: 1. Practicing at the Family Medicine Clinic of CSSS de Laval 2. Agree to participate and sign the consent form Community pharmacists: 1. Practicing in one of the pharmacies in the area of Laval or surrounding areas 2. Have one or more patients eligible for the study 3. Agree to participate and sign the consent form Patients: 1. 18 years old or older, either sex 2. Have an appointment at the Family Medicine Clinic of CSSS de Laval between October 2007 and March 2008 3. Takes at least five chronic medications 4. Reports being a patient of one of the participating pharmacies 5. Agrees to participate and sign the consent form 6. Is considered eligible by his family doctor

Exclusion criteria

Exclusion criteria: 1. Is not able to speak or read French 2. Is a patient of more than one community pharmacy 3. Is not able to give a informed consent

Design outcomes

Primary

Measure	Time frame
The following will be assessed after two months of follow-up: 1. Compare the mean number of DRP per patient identified by community pharmacists in both groups (intervention group and control group) 2. Compare the mean number of pharmacotherapy changes per patient between both groups (intervention group and control group)	—

Secondary

Measure	Time frame
The following will be assessed after two months of follow-up: 1. Compare the proportion of patients in each group for whom at least one intervention was made by the community pharmacists 2. For each type of intervention, compare the proportion of interventions made by the community pharmacists in both groups 3. Compare the proportion of pharmaceutical opinions that resulted in a pharmacotherapy change in both groups 4. Describe and compare the type of contact made between community pharmacists and Family Medicine Clinic?s pharmacists in both groups	—

Measure

Time frame

The following will be assessed after two months of follow-up: 1. Compare the proportion of patients in each group for whom at least one intervention was made by the community pharmacists 2. For each type of intervention, compare the proportion of interventions made by the community pharmacists in both groups 3. Compare the proportion of pharmaceutical opinions that resulted in a pharmacotherapy change in both groups 4. Describe and compare the type of contact made between community pharmacists and Family Medicine Clinic?s pharmacists in both groups

—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026